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the multivariate analysis, only IGF-1 level <–2 SDS (OR 13.3, 
95% CI 2.3–77.3) and complete GHD (OR 6.3, 95% CI 1.2–32.8) 
were associated with the outcome.  Conclusion: At final 
height, 56% of adolescents with GHD had recovered. Com-
plete GHD at diagnosis, low IGF-1 levels following retesting, 
and pituitary malformation were strong predictors of persis-
tence of GHD.  © 2015 S. Karger AG, Basel 
 Introduction 
 Among children presenting with short stature, approxi-
mately 10% have pathologic growth hormone deficiency 
(GHD)  [1] . The diagnosis of GHD is based on clinical pre-
sentation and results of dynamic testing  [2, 3] . Growth hor-
mone (GH) replacement therapy is an effective treatment 
in these children. Continuing GH treatment at the end of 
growth remains a clinically important question since GH is 
also available for adults  [4] . Beneficial effects of GH treat-
ment in adults include: increased periosteal bone forma-
tion and muscle mass, decreased fat mass, improved lipid 
profile and psychological well-being  [5–10] . However, pos-
sible negative effects of GH treatment include: increased 
insulin resistance, fluid retention with occasional edema, 
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 Abstract 
 Background/Aims: Controversies still exist regarding the 
evaluation of growth hormone deficiency (GHD) in child-
hood at the end of growth. The aim of this study was to de-
scribe the natural history of GHD in a pediatric cohort.  Meth-
ods: This is a retrospective study of a cohort of pediatric pa-
tients with GHD. Cases of acquired GHD were excluded. 
Univariate logistic regression was used to identify predictors 
of GHD persisting into adulthood.  Results: Among 63 identi-
fied patients, 47 (75%) had partial GHD at diagnosis, while 16 
(25%) had complete GHD, including 5 with multiple pituitary 
hormone deficiencies. At final height, 50 patients underwent 
repeat stimulation testing; 28 (56%) recovered and 22 (44%) 
remained growth hormone (GH) deficient. Predictors of per-
sisting GHD were: complete GHD at diagnosis (OR 10.1, 95% 
CI 2.4–42.1), pituitary stalk defect or ectopic pituitary gland 
on magnetic resonance imaging (OR 6.5, 95% CI 1.1–37.1), 
greater height gain during GH treatment (OR 1.8, 95% CI 1.0–
3.3), and IGF-1 level <–2 standard deviation scores (SDS) fol-
lowing treatment cessation (OR 19.3, 95% CI 3.6–103.1). In 
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pseudotumor cerebri, and carpal tunnel syndrome  [9, 11] . 
Furthermore, there are growing concerns about the long-
term effects of GH treatment with recent reports of an in-
creased risk of cardiovascular events, especially hemor-
rhagic stroke in adults treated with GH during childhood 
 [12–14] . For childhood-onset GHD, the transition period 
from adolescence to adulthood represents a critical time for 
reassessing GH status. At completion of growth (defined by 
bone age >14 years in girls and >16 years in boys or growth 
velocity <2 cm/year), about 40% of patients remain GH de-
ficient in adulthood  [15] . Importantly, as summarized in 
 table 1 , there is yet no consensus regarding the evaluation 
of GHD in adolescents at the end of growth in order to de-
fine which patients will benefit from continued GH treat-
ment despite a variety of protocols and proposed thresh-
olds to address this question  [2, 11, 15–19] . 
 Therefore, this study aimed to describe the natural his-
tory of GHD in a cohort of adolescents during the transi-
tion period and to identify predictors of GHD continuing 
into adulthood.
 Research Design and Methods 
 We studied a cohort of children with GHD who were treated at 
the University Hospital of Lausanne from 1998 to 2011. Adoles-
cents who completed growth with bone age >14 years in girls and 
>16 years in boys or growth velocity <2 cm/year were included. 
Cases of acquired GHD (i.e. trauma or oncology treatments) and 
individuals receiving GH for other indications (i.e. Turner syn-
drome, small for gestational age, SHOX gene haploinsufficiency, 
and chronic renal insufficiency) were excluded. 
 The diagnosis of GHD was based on the results of two provoca-
tion tests [insulin tolerance test (ITT), arginine (ARG) test, or glu-
cagon test with peak GH <10 μg/l] or one pathological test associ-
ated with structural pituitary abnormalities such as hypoplasia, 
stalk defect, or ectopic posterior pituitary on magnetic resonance 
imaging (MRI)  [3] . Priming with sex steroids was used before the 
stimulation test in prepubertal children >10 years of age. GH treat-
ment was conducted in a dose-dependent manner (0.15–0.20 mg/
kg/week) to normalize IGF-1 levels [between –2 and 2 standard 
deviation scores (SDS)]. 
 At completion of growth, GH status was reassessed by dynam-
ic testing and by serum IGF-1 measurement following a GH treat-
ment cessation (1–4 months). The ARG test was proposed in the 
majority of cases because of better tolerance compared to other 
tests  [16] . Adolescents with multiple (>2) pituitary hormone [GH, 
adrenocorticotropic hormone (ACTH), luteinizing hormone 
(LH), follicle stimulating hormone (FSH), or thyroid-stimulating 
hormone (TSH)] deficiencies  [20, 21] were considered GH defi-
cient without retesting and GH treatment was continued into 
adulthood without interruption. 
 We defined complete GHD as a peak GH <5 μg/l and partial 
GHD as a peak GH  ≥ 5–10 μg/l following stimulation at diagnosis 
and at final height, as proposed in prior studies  [15, 17] . The deci-
sion to continue GH treatment was based on the 1998 Growth Hor-
mone Research Society recommendations (peak GH of <3  μg/l) 
 [11] . The study was approved by the local ethics committee.
 GH concentrations were determined using a chemilumines-
cent immunoassay (CIA) with a System Luminometer 400 (Nich-
 Table 1.  Thresholds for diagnosing GHD at final height
Authors [Ref.], year Time of
reassessment
ITT GHRH-ARG
test
ARG test IGF-1 level
Growth Hormone
Research Society, 1998
adulthood <3.0 μg/l none given none given none given
Biller et al. [16], 2002 adulthood <5.0 μg/l;
sensitivity 95%;
specificity 92%
<4.1 μg/l;
sensitivity 95%;
specificity 91%
<1.4 μg/l;
sensitivity 95%;
specificity 62%
<–2 SDS;
sensitivity 46%;
specificity 100%
Maghnie et al. [18], 2005 at transition <6.1 μg/l;
sensitivity 96%;
specificity 100%
none given none given <–1.7 SDS;
sensitivity 77%;
specificity 100%
Corneli et al. [19], 2007 at transition none given <19.0 μg/l;
sensitivity 100%;
specificity 97%
none given none given
Secco et al. [28], 2009 at transition <5.62 μg/l;
sensitivity 77%;
specificity 93%
none given none given <–2.83 SDS;
sensitivity 80.7%;
specificity 95.7%
 Previously published stimulation tests with respective cutoff values of GH (μg/l). ITT and GHRH-ARG test demonstrated the best 
sensitivity and specificity for evaluating GHD following treatment (final height).
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.1
 - 
4/
11
/2
01
6 
10
:0
5:
12
 A
M
 Deillon   et al. Horm Res Paediatr 2015;83:252–261
DOI: 10.1159/000369392
254
ols Institute Diagnostics, Bad Nauheim, Germany; study period 
1998–2004). The CIA assay has an analytical sensitivity of 0.2 μg/l 
with an intra-assay coefficient of variation (CV) of 4.0–5.4% and 
an inter-assay CV of 7.9–9.2%. From 2004 on, the automated CIA 
Immulite 2000 (Siemens Healthcare Diagnostics Inc., Erlangen, 
Germany) was used with an analytical sensitivity of 0.05 μg/l, an 
intra-assay CV of 2.9–4.6%, and an inter-assay CV of 4.2–6.6%. 
The GH calibration standard used for both platforms was the 
WHO NIBSC (1st 80/505 until December 2009 and 2nd 98/574 
thereafter). IGF-1 concentrations were determined by a radioim-
munoassay from Nichols Institute Diagnostics (study period 
1998–2005). The radioimmunoassay had an analytical sensitivity 
of 15 μg/l, an intra-assay CV of 2.4–3.0%, and an inter-assay CV of 
5.2–8.4%. From 2005 on, the automated CIA Immulite 2000 (Sie-
mens Healthcare Diagnostics Inc.) was used. The automated assay 
has an analytical sensitivity of 35 μg/l, an intra-assay CV of 2.3–
3.9%, and an inter-assay CV of 3.7–8.1%. The WHO NIBSC 1st 
IRR 87/518 was used for IGF-1 calibration throughout the entire 
study period. IGF-1 data were transformed into sex- and age-re-
lated SDS values using previously published data  [22] .
 Statistical Analysis 
 Data are presented as means ± standard deviations (SD). Cat-
egorical data are presented using descriptive statistics. Predictors 
of persisting GHD were examined using logistic regression analy-
sis. The strength of the association measured by the odds ratio 
(OR) and significant predictors at the level of 5% from the uni-
variate analysis were used in a forward procedure to fit a multi-
variate model. Confirmation of OR results included nonparamet-
ric bootstrap analysis (replication ×100). Data analysis was per-
formed using STATA-12 software (Stata Statistical Software, 
release 12, StataCorp 2011, College Station, Tex., USA).
 Results 
 One hundred and sixty-two children with GHD were 
treated at the University Hospital of Lausanne between 
1998 and 2011, 82 of whom had completed their growth. 
Of these 82 patients, 19 (23%) had acquired forms of 
GHD and were excluded, while the remaining 63 adoles-
cents with congenital or idiopathic GHD (77%) were in-
cluded in the analysis. 
 Characteristics of the GH-Deficient Cohort at 
Diagnosis  
 Three quarters of the cohort (47/63) exhibited partial 
GHD (75%), while 16/63 had complete GHD (25%) 
( fig. 1 ). In total, 42 (67%) were boys and 21 (33%) girls. 
The diagnosis was made at a mean age of 9.5 ± 3.6 years. 
The mean height was –2.4 ± 0.7 SDS at diagnosis with a 
delayed bone age of 2.2 ± 1.1 years. Twenty subjects 
(20/63) exhibited pituitary malformation (32%) includ-
ing 11/20 with complete GHD (55%) and 9/20 with par-
tial GHD (45%) at diagnosis ( fig. 1 ). Six boys and 2 girls 
(>10 years of age) were diagnosed with partial GHD after 
priming with sex steroids. Clinical, radiologic, and bio-
chemical characteristics of subgroups (partial GHD, n = 
47, and complete GHD, n = 16) are presented in  table 2 . 
All patients with partial GHD had isolated GHD, while 
patients with complete GHD included 5 children with 
multiple pituitary hormone deficiencies (MPHD). Three 
children had >2 pituitary hormone deficiencies associat-
ed with SOD (n = 1) and ectopic posterior pituitary gland 
(n = 2). The 2 other children with MPHD included 1 girl 
with TSH and GH deficiencies associated with stalk de-
fect and ectopic posterior pituitary gland on MRI and 1 
boy with GH and LH/FSH deficiency as well as pituitary 
hypoplasia ( table 2 ). 
 GH Reassessment at Final Height  
 At final height, 50/63 children were retested for GHD 
( fig. 1 ). Three patients with MPHD were considered GH 
deficient without treatment interruption and were inte-
grated into statistical analyses as GH deficient. The other 
10 were lost to follow-up. The vast majority of patients 
(47/50) underwent ARG testing, while 2 had an ARG-ITT 
test and 1 an ITT. Nine out of 50 (18%) patients showed 
complete GHD, 13/50 (26%) partial GHD, and 28/50 
(56%) recovered. The rate of reversal (according to differ-
ent cutoffs) among the diagnostic subgroups is presented 
in  figure 1 . Seven of the 63 patients in this cohort contin-
ued GH treatment into adulthood: 4 had a peak GH <3 μg/l 
and an IGF-1 level <–2 SDS and 3 patients with MPHD 
(>2) were considered GH deficient at adulthood ( fig. 1 ). 
 GH Reassessment of Patients with Partial GHD at 
Diagnosis
 Of the 47 patients with partial GHD at initial diagno-
sis, 37 had repeat stimulation testing at final height 
( fig.  1 ). In total, 25/37 (68%) patients recovered, 9/37 
(24%) patients remained with partial GHD, and 3/37 
(8%) patients worsened to complete GHD ( fig. 1 ,  2 ). Im-
portantly, no adolescent initially diagnosed with partial 
GHD had a GH peak <3 μg/l and none of these patients 
continued GH treatment into adulthood. The 3 adoles-
cents who had worsening deficiency with complete GHD 
at final height had a peak GH between 3 and 5 μg/l. Two 
had an IGF-1 level >–2 SDS and no pituitary abnormali-
ties on MRI, while 1 patient exhibited ectopic posterior 
pituitary on MRI at final height. 
 Four of the 9 children that remained partially GH de-
ficient showed IGF-1 levels <–2 SDS. One had pituitary 
hypoplasia. Of the 25/37 patients who recovered from 
partial GH deficiency, 3 had pituitary malformations (2 
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with hypoplasia and 1 with ectopic posterior pituitary), 
while IGF-1 levels were  ≥ –2 SDS. The other 22 patients 
without pituitary anomalies had idiopathic GHD (88%). 
Two of these children had IGF-1 levels <–2 SDS but a GH 
peak >20 μg/l ( fig. 1 ).
 GH Reassessment of Patients with Complete GHD at 
Diagnosis 
 Thirteen of the 16 patients had a stimulation test at fi-
nal height ( fig. 1 ). Nearly half of the patients remained 
with complete GHD after stimulation (6/13, 46%), while 
4/13 (31%) patients improved to partial GHD and 3/13 
(23%) patients recovered ( fig. 1 ,  2 ). Three patients with 
MPHD were considered GH deficient without testing.
 One of the children with complete GHD (peak GH lev-
el 3.3 μg/l after ARG test) was not treated as the peak GH 
was >3 μg/l  [11] . This child had ectopic posterior pituitary 
on MRI but exhibited IGF-1 levels >–2 SDS after treat-
ment interruption.
 Two adolescents who improved to partial GHD had 
IGF-1 <–2 SDS. One had idiopathic GHD, while the oth-
er had stalk defect and ectopic posterior pituitary. In ad-
dition, the latter had MPHD (GH and TSH). One of the 
3 children with recovery showed MPHD (GH and FSH/
LH) associated with pituitary hypoplasia and severe obe-
sity. Following puberty induction and weight loss, this 
adolescent recovered from GHD and gonadotropin defi-
ciency. The 2 others had isolated GHD ( fig. 1 ,  2 ). 
GHD in a pediatric cohort excluding acquired forms
(n = 63) 100%
Partial GHD
(n = 47) 75%
Complete GHD
(n = 16) 25%
Isolated GHD
(n = 11)
MPHD
(n = 5)
>2 PHD (3/5)
Pituitary malformation
(n = 5) 100%###
Pituitary malformation
(n = 6) 55%##
Pituitary malformation
(n = 9) 19%##
Idiopathic GHD
(n = 38) 81% 
Idiopathic GHD
(n = 5) 45% 
Recovery:
10 μg/l: n = 22 (73%)
Partial GHD:
5–10 μg/l: n = 6 (20%)
Complete GHD:
<5.0 μg/l: n = 2 (7%)
GH treatment:
<3.0 μg/l: n = 0 (0%)
<6.1 μg/l: n = 7 (23%)
Recovery: #
10 μg/l: n = 3 (43%)
Partial GHD: #
5–10 μg/l: n = 3 (43%)
Complete GHD:
<5.0 μg/l: n = 1 (14%)
GH treatment:
<3.0 μg/l: n = 0 (0%)
<6.1 μg/l: n = 4 (57%)
Recovery:
10 μg/l: n = 1 (20%)
Partial GHD:
5–10 μg/l: n = 3 (60%)
Complete GHD:
<5.0 μg/l: n = 1 (20%)
GH treatment:
<3.0 μg/l: n = 1 (20%)
<6.1 μg/l: n = 3 (60%)
Recovery:
10 μg/l: n =1 (17%)
Partial GHD: #
5–10 μg/l: n = 0 (0%)
Complete GHD: #
<5.0 μg/l: n = 5 (83%)
GH treatment:
<3.0 μg/l: n = 3 (50%)
<6.1 μg/l: n = 5 (83%)
Recovery:
10 μg/l: n =1 (50%)*
Partial GHD: #
5–10 μg/l: n = 1 (50%)**
Complete GHD: 
<5.0 μg/l: n = 0 (0%)
GH treatment: ##
MPHD without test ( n = 3)
<6.1 μg/l: n = 0 (0%)
n = 7 n = 5 n = 6
Retesting after discontinuation of GH treatment at final height (n = 50)
n = 30 n = 2
 Fig. 1. Diagnostic subgroups of childhood-onset GHD at diagnosis 
and at the end of GH treatment (final height) using different cut-
offs. Pituitary malformation includes pituitary hypoplasia, stalk 
defect, or ectopic posterior pituitary. MPHD includes >2 pituitary 
hormone deficiencies (n = 3). Patients with >2 pituitary hormone 
deficiencies (n = 3) were not retested but considered GH deficient 
and included in the statistical analysis (arrow). PHD = Pituitary 
hormone deficiencies.  *   GH and LH/FSH deficiencies (n  = 1); 
 * *  GH and TSH deficiencies (n = 1);  #  patients with ectopic pitu-
itary gland (n of symbols = n of patients).  
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 GH Reassessment According to Pituitary Anomalies 
at Diagnosis 
 At final height, 15/20 young patients with pituitary 
anomalies at diagnosis were reevaluated by stimulation 
test, and 3 children with MPHD were considered GH 
deficient ( fig. 1 ). Among the patients with pituitary mal-
formation, 5 (33%) recovered, including 1 out of 5 re-
tested patients with ectopic posterior pituitary gland. 
Only 1 patient with ectopic posterior pituitary gland 
showed a GH peak <5 μg/l ( fig. 1 ). In our series, 35 pa-
tients had no pituitary malformation. Of those, 23 (66%) 
recovered. 
 IGF-1 Reassessment at Final Height after Treatment 
Interruption 
 Plasma IGF-1 levels after treatment interruption were 
measured in 52/63 adolescents. In 14 adolescents, IGF-1 
levels were <–2 SDS at reevaluation ( table 2 ). Two adoles-
cents who showed IGF-1 levels <–2 SDS recovered. These 
2 children showed no pituitary malformation and peak 
GH levels at reassessment of >20 μg/l.
 Predictors of Persisting GHD at Final Height 
 We evaluated several factors predicting the persis-
tence of GHD into adulthood ( table 3 ). Positive predic-
tors included: (1) IGF-1 levels <–2 SDS following discon-
tinuation of GH treatment (OR 19.3); (2) complete GHD 
at diagnosis in childhood (OR 10.1); (3) pituitary malfor-
mation at diagnosis (OR 5.6), especially stalk defect and/
or ectopic posterior pituitary (OR 6.5), and (4) height 
gain of 1 SDS on treatment (OR 1.8). Data are summa-
rized in  table 3 . 
 When multivariate logistic regression was used, only 
complete GHD at diagnosis and an IGF-1 level <–2 SDS 
following GH treatment cessation were significant as in-
dependent positive predictors. Furthermore, when these 
two factors were combined, the sensitivity and specificity 
was the highest. The obtained Hosmer-Lemeshow test of 
goodness-of-fit p value was 0.68 and the area under the 
ROC curve was 0.81 ( fig. 3 ).
 Table 2.  Clinical, radiologic, and biochemical characteristics of 63 
children with childhood-onset GHD divided into diagnostic sub-
groups
Partial/
isolated 
GHD 
(n = 47)
 Complete GHD (n = 16)
iso lated 
GHD
(n = 11)
MPHD
(n = 5)
Clinical and radiological characteristics at diagnosis
Age, years 9.5±3.6 9.0±4.7 9.5±7.4
Sex ratio, f/m 17/30 2/9 2/3
Height SDS –2.4±0.6 –2.7±0.8 –2.1±1.3
BMI SDS –0.2±2.1 0.7±2.0 3.7±3.5
Delayed bone age, years 2.1±1.06 
(n = 38)
2.5±1.6 2.1±1.2
Pituitary on MRI
Hypoplasia/aplasia 6 4 2
Stalk defect 3 3 4
Ectopic posterior pituitary 2 2 3
Septo-optic dysplasia 0 1 2
Clinical and biochemical characteristics at final height 
(cessation of GH treatment)
Age, years 16.6±1.3 16.8±1.9 18.0±2.1
Final height SDS –0.89±0.7 –0.7±1.8 0.1±1.5
Height gain SDS 1.47±0.7 1.99±1.38 2.19±2.13
IGF-1 <–2 SDS, n/total n 6/38 6/11 2/3
 Values are means ± SD or numbers, unless otherwise indicated. 
8%
24%
68%
46%
31%
23%
<5
5–10
GH peak after stimulation (μg/l)
10
0
20
40
60
80
Pe
rc
en
ta
g
e 
(%
)
Partial GHD in childhood
Complete GHD in childhood
 Fig. 2. GH peak response to stimulation 
testing at the end of treatment (final height) 
in patients with complete GHD (grey) and 
partial GHD (white) at diagnosis in child-
hood. Complete GHD defined by peak GH 
<5 μg/l. Partial GHD defined by peak GH 
 ≥ 5–10 μg/l. Recovery of GHD defined by 
peak GH >10 μg/l at stimulation. 
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 Discussion 
 We studied the natural history of GHD (excluding 
acquired cases) in a cohort of 63 children. Our retro-
spective study revealed that 44% of adolescents re-
mained deficient at the end of growth, while 56% had 
recovered. As expected, the majority (89%) of those ad-
olescents who had recovered had partial GHD at diag-
nosis. Yet, more than half (54%) of the children with 
complete GHD improved, with nearly a quarter (23%) 
exhibiting recovery. Furthermore, 8% of the patients 
with partial GHD at diagnosis worsened and had com-
plete GHD at reevaluation, but none of these children 
met the criteria for GH treatment into adulthood. These 
data suggest a plasticity of the GH axis among children 
diagnosed with GHD.
 We identified several predictors of persistent GHD in 
adulthood: IGF-1 <–2 SDS at reassessment (OR 19), com-
plete versus partial GHD at diagnosis (OR 10), pituitary 
malformations versus idiopathic GHD (OR 5.6), and 
height gain of >1 SDS after treatment (OR 1.8). These 
findings are clinically important as they can help to direct 
the assessment of those patients who may require ongo-
ing GHD treatment into adulthood. 
 This work departs from previous studies in that we ex-
cluded acquired GHD and focused exclusively on con-
genital and idiopathic forms of GHD. The rationale for 
excluding acquired forms was that the potentially con-
founding variables introduced by oncological treatment, 
tumor, or trauma make the interpretation of the natural 
history data much less clear. Instead, we concentrated on 
a cohort with potentially, yet likely, genetic etiology un-
derlying GHD. 
 The retrospective study is limited by the relatively 
small sample size, as evidenced by quite wide confidence 
intervals. Therefore, harmonization of stimulation test-
ing and establishing set cutoff values in a prospective 
multicenter approach seems imperative for future studies 
to clarify the reassessment of GH status. 
 Table 3.  Predictors of persisting GHD at the end of growth (final height)
Predictors OR 95% CI p value
IGF-1 <–2 SDS (1–4 months after GH treatment cessation) 19.3 3.6–103.1 0.001
Complete GHD vs. partial GHD at diagnosis 10.1 2.4–42.1 0.001
Pituitary malformation on MRI vs. idiopathic GHD 5.6 1.6–19.4 0.006
Stalk defect/ectopic posterior pituitary vs. idiopathic GHD 6.5 1.1–37.1 0.035
Height gain (by 1 SDS) during treatment 1.8 1.0–3.3 0.048
Sex 2.29 0.72–7.3 0.163
Age at diagnosis 0.91 0.79–1.06 0.224
Bone age retardation (years) 1 0.85–1.17 0.964
Height at diagnosis (SDS) 0.73 0.34–1.59 0.428
Weight at diagnosis (SDS) 1.04 0.73–1.48 0.847
BMI at diagnosis (SDS) 1.05 0.81–1.36 0.723
Puberty retardation (standardized)a 1.04 0.79–1.06 0.84
 a Age at puberty onset – mean age at puberty onset according to Tanner for a reference population.
0
0.25
0.50
0.75
1.00
Se
n
si
ti
vi
ty
0 0.25 0.50 0.75 1.00
Ref.
(3) = (1) + (2), AUC = 0.81
(1) Complete GHD at diagnosis, AUC = 0.71
(2) IGF-1 level <–2 SDS following GH treatment cessation, 
AUC = 0.75
1 – specificity
 Fig. 3. Diagnostic performance of complete GHD at diagnosis and 
IGF-1 levels after treatment cessation for predicting persisting 
GHD at the end of growth (final height). These two predictors have 
a discrimination power of 81% (area under the ROC curve  = 
0.8118). Complete GHD defined by peak GH response <5 μg/l af-
ter stimulation. AUC = Area under the ROC curve. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.1
 - 
4/
11
/2
01
6 
10
:0
5:
12
 A
M
 Deillon   et al. Horm Res Paediatr 2015;83:252–261
DOI: 10.1159/000369392
258
 Similar to previous studies, we report a high recovery 
rate in children with partial GHD  [15, 23] . Compared to 
the study of Tauber et al.  [15] , including a similar cohort 
of 131 children with GHD (i.e. peak GH <5 μg/l for com-
plete GHD and peak GH  ≥ 5–10 μg/l for partial GHD), we 
report a slightly lower recovery rate (56 vs. 62%). This 
difference may be accounted for by the fact that the previ-
ous study included more idiopathic cases (92 vs. 68%, re-
spectively) and did not include sex steroid priming at the 
time of puberty. Notably, priming has been suggested by 
Carel et al.  [24] as a means to rule out GHD in children 
with constitutional growth delay. Our clear predomi-
nance of GHD in males compared to females (2: 1) ( ta-
ble 2 ) is consistent with the existing literature  [17, 25–27] . 
Such gender discordance, as in the case of other develop-
mental disorders such as Kallmann syndrome, can poten-
tially be explained by ascertainment bias, i.e. boys are 
much more likely to present because of short stature than 
girls. However, the contribution of X-linked genes, epi-
genetics, or male susceptibility to prenatal or perinatal 
insult may also be important contributors to this phe-
nomenon. 
 Importantly, we identified predisposing factors for 
persistence of GHD, such as IGF-1 levels. Indeed, the 
relationship between IGF-1 levels and GH peak has been 
previously demonstrated  [15] . Yet, IGF-1 levels <–2 SDS 
have not been shown to be particularly sensitive predic-
tors (46%), but have a specificity of 100% ( table 1 )  [16] . 
Secco et al.  [28] evaluated the accuracy of IGF-1 mea-
sures in defining permanent GHD. The ROC curve anal-
ysis of IGF-1 showed the best diagnostic accuracy with 
lower IGF-1 levels, i.e. –2.83 SDS ( table 1 ). In contrast, 
Quigley et al.  [27] studied potential predictors of persist-
ing GHD and found that IGF-1 levels did not have a 
positive predictive value. They proposed using IGF-1 
levels >1.6 SDS to predict GH sufficiency. The 2 adoles-
cents who recovered with IGF-1 levels <–2 SDS in our 
cohort point to the problem of using only one factor to 
identify persisting GHD. However, the sensitivity for 
predicting persisting GHD was improved when an ad-
ditional factor (complete GHD at diagnosis) was added 
( fig. 3 ).
 In the present study, gain of height during treatment 
was identified as a novel predictor of persisting GHD (OR 
2). As our patients were treated in a dose-adjusted man-
ner, this is consistent with a greater GH treatment effect 
in those patients with more severe GHD and is in line 
with a better response to GH treatment in patients with 
pituitary imaging abnormalities. Thus, a more severe 
phenotype may be indicative of GHD persisting into 
adulthood  [25, 27] . However, there is a need for reassess-
ment of this population to identify patients who may re-
cover function. 
 The recovery rate of 20% in our patients with ectopic 
posterior pituitary is similar to rates reported by Gelwane 
et al.  [29] who identified recovery (peak GH >10 μg/l) in 
6 of 24 (25%) patients with ectopic posterior pituitary. In 
contrast to prior studies  [30, 31] , we did not find perma-
nent severe GHD in 100% of patients with pituitary stalk 
interruption syndrome.
 Among those patients with partial GHD at diagnosis, 
none had a GH peak <3 μg/l at reassessment, yet 6 of the 
patients had IGF-1 levels <–2 SDS after treatment inter-
ruption. Thus, it appears that an IGF-1 level >–2 SDS in 
a patient with partial GHD would not necessarily require 
dynamic testing. This would be a novel clinical implica-
tion emerging from these data. In effect, such a practice 
would reduce the number of repeat stimulation tests in 
young patients diagnosed with partial GHD and should 
have time- and cost-saving impacts while reducing the 
risk of adverse testing events. 
 Despite these novel findings, several important ques-
tions relating to GH reassessment at the end of growth 
remain unanswered. Salient issues include the optimal 
test and cutoffs, GH immunoassay sensitivity, and clin-
ical outcomes in patients with or without treatment. 
Also, the time of retesting warrants further examina-
tion, as Darendeliler et al.  [23] demonstrated that 69% 
of children with partial GHD recover prior to comple-
tion of growth. As summarized in  table 1 , stimulation 
tests have a huge variability in cutoff values depending 
on age and test used. The fact that recommendations 
have changed over time further complicates retrospec-
tive interpretations, which explains why we and others 
have utilized different cutoffs  [15, 17] . Importantly, it 
remains to be clarified if adopting higher thresholds for 
stimulated GH peak in young adults could be beneficial 
for long-term bone health and fracture protection. 
GH has important effects on bone formation, particu-
larly cortical thickness  [32, 33] . Using appropriate size 
corrections, bone density in children with isolated GHD 
is normal  [34] . Indeed, supplementation of GH increas-
es bone turnover and increases trabecular bone score 
reflecting bone remodeling in favor of improving its 
quality  [35] . However, there is yet no clear evidence of 
increased fracture risk of patients with childhood-onset 
isolated GHD  [10] . Achieving final adult height occurs 
much earlier than the acquisition of peak bone mass 
and muscle strength  [36] . Accordingly, continuation of 
GH treatment at the end of growth could also help op-
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timize muscle development, which may in turn have a 
positive effect on bone strength and may minimize frac-
ture risk. 
 During transition, the ITT is the gold standard test. 
The GH-releasing hormone (GHRH)-ARG test with a 
similar sensitivity and specificity as shown in  table 1 can 
be used as an alternative, but proposed cutoff values for 
this test show a high variability that seems to be related 
to body mass index (BMI)  [16, 19] . The proposed thresh-
old GH value after ITT among young adults is 6.1 μg/l 
 [37] . Using this threshold, more patients would have 
been identified for GH treatment at the end of growth 
(19/50, vs. 4/50 patients). This includes 10 additional 
patients with partial GHD and 5 patients with complete 
idiopathic GHD. To identify the cutoff value proposed 
by Maghnie et al.  [38] , or more recently the cutoff value 
of 5.6 μg/l proposed by Secco et al.  [28] , MPHD and/or 
pituitary malformation was used as the gold standard to 
define probable permanent GHD. However, this is not 
perfect as we and others have demonstrated that patients 
with pituitary malformation as well as MPHD can re-
cover  [17] . In addition, androgen treatment in those 
GHD patients with pubertal delay may be another im-
portant factor. For instance, recovery of hypothalamic-
pituitary-gonadal axis function has been demonstrated 
in patients with Kallmann syndrome following sex ste-
roid treatment  [39, 40] . Furthermore, there is a genetic 
overlap between gonadotropin-releasing hormone 
(GnRH) deficiency and MPHD  [41] , thus suggesting a 
possible molecular basis for the recovery observed in 
these two developmental endocrine disorders. So, ques-
tions regarding an accepted gold standard remain. Fur-
ther, standardized GH assays with appropriate quality 
control are critical for interpreting results  [3, 11, 42] . 
Importantly, this aspect has not been given much atten-
tion to this point in time and merits consideration when 
relevant thresholds to guide clinical management are es-
tablished. 
 While predictors can be useful in guiding care dur-
ing the transition period, none of these factors will have 
a 100% specificity and sensitivity. Indeed, long-term 
follow-up of adolescents receiving GH therapy seems 
appropriately warranted  [20] . Additionally, documen-
tation of bone health, BMI, and quality of life will also 
be a contributing factor to the decision-making process 
regarding the need for GH treatment in young adult-
hood. For example, an increase in body fat and a de-
creased lean body mass 1 year after GH treatment inter-
ruption has been documented in a group of patients 
with partial GHD  [43] . Thus, the clinical pathway for 
GHD patients involves numerous important health 
outcome variables. 
 The results of our analysis at the end of growth point 
to several critical questions pertaining to diagnosis in 
childhood, GH immunoassay sensitivity, and reassess-
ment. In relation to diagnosis, there are a variety of tests 
used in childhood (i.e. ITT, ARG test, glucagon, etc.) as 
well as different assays. Indeed, the sensitivity of GH as-
says has improved over time and the GH assays that 
were used to diagnose many of the patients in the pres-
ent study are not optimal. However, pediatric diagnosis 
is not solely based on test results but always corrobo-
rated with clinical and radiologic findings. Reassess-
ment remains an important question. Secco et al.  [28] 
identified predictors by correlating peak GH values at 
diagnosis (albeit using GH assays with suboptimal sen-
sitivity) with outcomes in adulthood. They confirmed 
that the ITT is an accurate test in the reevaluation of 
GHD in children at the end of growth and that IGF-1 is 
a reliable marker for persistence of GHD. These data 
combined with the present study identify several predic-
tors of persisting GHD in adulthood and underscore re-
maining questions. Importantly, these predictors should 
be confirmed by further studies with harmonized testing 
procedures and standardized cutoffs. Additionally, re-
peat testing during childhood may help improve the ac-
curacy of diagnosis of GHD, and long-term follow-up is 
warranted to ensure that those cases of reversal remain 
normally functioning.
 In conclusion, this retrospective study documents 
the natural history of GHD at the end of growth in a 
cohort of children with GHD excluding acquired forms. 
We identified several predictors of persisting GHD at 
final height: complete GHD at diagnosis, IGF-1 levels 
<–2 SDS following treatment cessation, pituitary mal-
formation on MRI, and greater height gain during GH 
treatment. However, important questions remain re-
garding the continuation of GH treatment at the end of 
growth. These data underscore the paucity of data com-
paring dynamic testing regimens in this population that 
preclude the development of evidence-based guidelines. 
We propose using the ITT as the most extensively vali-
dated test in young adults during transition. Genetic 
findings on GHD may provide additional insights into 
the molecular basis for recovery of adolescents with 
GHD. Finally, long-term follow-up of these patients 
evaluating health-related outcomes may also contribute 
to the decision-making process for continuing GH 
treatment. 
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